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Abstract
OBJECTIVES: The aim of this study was to investigate new therapeutic options to attenuate acute rejection in a rat lung allograft model.
Cell-based gene therapies have recently been reported as a novel curative option in acute and chronic diseases for which conventional
treatments are not available. We studied the effect of human interleukin 10 (hIL-10) on expressing bone marrow-derived mesenchymal
stem cells (BMSCs) in combination with cyclosporine A (CsA) on acute rejection of lung allografts in the rat.
METHODS: Lung allotransplantation was performed from male Brown Norway donor to male Fisher (F344) rats. Rat BMSCs were trans-
fected with hIL-10 in vitro and introduced in the graft prior to implantation. Group A (n = 5) received CsA intraperitoneally (2.5 mg/kg body
weight) for 5 days post-transplant; Group B (n = 5) received BMSC and CsA and Group C (n = 5) received hIL-10-BMSC before implantation
and CsA. Graft function was assessed by blood gas levels only from the graft on day 5; tissue was sampled for histological grading of rejec-
tion and measurement of the wet-to-dry ratio.
RESULTS: All Group A control animals showed severe signs of rejection. On Day 5, all grafts in Group C showed improved gas exchange
(mean arterial partial pressure of oxygen 222.2 ± 40.38 mmHg vs 92.36 ± 20.92 mmHg in Group B and 42.72 ± 18.07 mmHg in Group A).
Histological examination revealed moderate-to-severe rejection in all animals in Group A [International Society for Heart and Lung
Transplantation Level III B (ISHLT)] in contrast to low-to-moderate rejection in Group B (II–IIIA) and much improved histological grade in
Group C (I–IIA). Moreover, the wet-to-dry ratio was also reduced in Group C (4.8 ± 1.19 compared with 4.78 ± 0.62 in Group B and
9.36 ± 0.90 in Group A).
CONCLUSIONS: The hIL-10 BMSC represent a promising novel method for localized cell-based gene therapy for acute rejection in a rat
lung allograft model.
Keywords: Lung transplantation • Stem cells • Acute rejection • IL-10
INTRODUCTION
Lung transplantation is the only treatment option for a variety
of end-stage lung diseases such as chronic obstructive pulmonary
disease, interstitial lung disease and cystic fibrosis [1]. However,
survival after a lung transplant is still not particularly promising
compared with that after other solid organ transplants [2, 3],
with only 53% survival reported 5 years after the transplant
[1]. Approximately 33% of the patients develop acute rejection
in the first year after the transplant, which is related to the
development of chronic rejection and reduced survival.
Various attempts have been made to attenuate acute rejection;
however, the results are not promising [2]. Induction therapy,
which involves intensive immunosuppressant therapy given
perioperatively to reduce acute rejection and to delay the
initiation of maintenance immunosuppression, was recently
introduced [2]. The most commonly applied induction agent
is the interleukin 2 receptor antagonist [4]. Despite these
advances, the survival rate is low. Therefore, novel approaches
that could attenuate acute rejection and improve survival are
required.
†Presented at the 29th Annual Meeting of the European Association for
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In previous studies, we successfully applied the electro-
poration-mediated gene transfer of human interleukin 10 (hIL-10)
to the recipient prior to implantation to attenuate acute rejection
in a lung transplant model [5]. However, the dose of hIL-10
was high and the route of administration was systemic. Therefore,
we reduced the dose of hIL-10 and provided a more localized
application using IL-10 modified bone marrow-derived stem
cells.
Bone marrow-derived mesenchymal stem cells (BMSCs) are
known to have immunogenic and anti-inflammatory properties
and have been tested in various disease models [6], including a
rat heart transplant model [7]. BMSC cell therapy has been re-
ported in acute and chronic lung injury models [8, 9]. Stem cells
can also be used as a vehicle to carry the gene [10–12].
Moreover, cell-based gene therapy is a promising approach for
localized and targeted applications and has been applied in a
chronic lung injury model [13]. The BMSCs are transfected with a
gene of interest in vitro and administered in vivo. We
hypothesized that this approach has an additive effect locally and
can be of benefit in attenuating acute rejection in a lung trans-
plant model. In the current study, we tested whether BMSCs that
overexpress IL-10 when administered in the graft before implant-
ation can attenuate acute rejection in a rat lung allograft model.
MATERIALS AND METHODS
Animal ethics approval
All animals received humane care in compliance with the
‘Principles of Laboratory Animal Care’, formulated by the
National Society for Medical Research, and the ‘Guide for the
Care and Use of Laboratory Animals’ prepared by the Institute of
Laboratory Animal Research. Experiments were performed in ac-
cordance with the standards of the European Convention of
Animal Care. The animals were kept in air- and temperature-
controlled cages. At no time were the animals deprived of food
and water. The protocol was approved by the University of Bern
animal study committee. ARRIVE guidelines were followed to re-
port the data (see Supplementary material, File S1).
Isolation and culture of rat bone marrow-derived
mesenchymal stem cells
BMSCs were isolated from recipients (Fisher F344 rats). The ani-
mals were anaesthetized by inhalation of 4% isoflurane in a glass
chamber, followed by intraperitoneal administration of thiopen-
tal (50 mg/kg body weight). The femur and tibia from the
hindlimbs were dissected, and the skin and muscles were
removed. The isolated femur and tibia were placed in 70% etha-
nol for 30 s and then transferred in fresh phosphate-buffered sa-
line (PBS; 1 PBS). The bones were cut at the ends with a bone
cutter and flushed with 1 ml of 1 PBS using a 22-G needle. The
flow-through liquid was collected in a sterile tube; each bone
was flushed 2–3 times with a volume of 1 ml each time. After
centrifugation, the cells were resuspended in Iscove’s modified
Dulbecco’s medium supplemented with 10% PBS and 1% penicil-
lin/streptomycin medium and plated in 75-cm flasks and placed
at 37C in a 5% carbon dioxide incubator. After 3 days, the me-
dium was changed; subsequently, the medium was changed
every day. For the experiments, the cells were used at Passages
2–4. Ten F344 animals were used to isolate the BMSCs. The cells
were counted using the Countess Cell Counter (Invitrogen,
Thermo Fisher Scientific, Waltham, MA, USA).
Transfection of rat bone marrow-derived mesen-
chymal stem cells
Rat BMSCs were transfected with the plasmid pCikhIL-10, hIL-10
driven by the human cytomegalovirus early promoter enhancer
as described [5] with the Amaxa nucleofection (Lonza, Allendale,
NJ, USA) using U-23 settings according to the manufacturer’s
protocol; 5 105 cells were transfected in 1 cuvette with 1 mg of
hIL-10 plasmid. After transfection, the cells were kept in warm
media and placed at 37C in a 5% carbon dioxide incubator
overnight. Next morning, a total of 2 106 cells were introduced
in the explanted graft approximately 2 h before implantation in
the recipient. The Amaxa (Lonza AG, Switzerland) nucleofection
works on the concept of in vitro electroporation. Electroporation
is a physical method of gene transfer that involves the application
of a high voltage to the cells for a very short period.
Electroporation makes the cell membrane permeable, thus ena-
bling the transfer of the DNA inside the cell for a successful trans-
fection. For experimental purposes, all of the cells were used, and
no prior sorting of the transfected cells was performed.
Flow cytometry
The immunophenotype of the cell surface was analysed by stain-
ing the BMSCs with fluorescein isothiocyanate-labelled monoclo-
nal antibodies against antihuman IL-10 antibody. After
trypsinization, the cells were resuspended in PBS to obtain a
single-cell suspension, washed and incubated for 45 min at 4C
in the dark with the staining antibody. Unbound antibody was
removed by washing the cells 3 times in staining buffer (1% bo-
vine serum albumin and 0.1% sodium azide in PBS) at 4C. The
cells were then resuspended in staining buffer and analysed with
the FACScan (Becton Dickinson, Franklin Lakes, NJ, USA). The
stem cells were divided in 2 tubes, with 1 tube containing cells
that were not transfected. These are indicated by the red graph
in Fig. 1 and represent the negative population. The stem cells in
the second tube were transfected with hIL-10 as explained previ-
ously and were gated based on the threshold of the autofluores-
cence obtained from the non-transfected cells. We then
measured the intensity of the fluorescence in the transfected
stem cells (the blue graph in Fig. 1). After transfection, BMSC
were not sorted for positive cells; rather we used the whole
population of BMSC for the experiments.
Experimental groups
Left lung allotransplantation was performed in rats with major
full mismatch and 1 minor immunological mismatch (donor:
Brown Norway; recipient: Fischer F344) [5]. Recipients were ran-
domly divided into 3 groups (n = 5): Group A animals received
CsA 2.5 mg/kg/day intraperitoneally starting on the day of the
transplant. Group B (n = 5) received CsA daily in combination
with BMSC introduced into the graft 2 h before the implantation.
Group C (n = 5), the implanted graft, was given BMSC-hIL10, i.e.
BMSC transfected with 1 lg of hIL-10 plasmid DNA (pCik hIL-10)
24 h before the operation. All animals in Group C also received
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CsA. During the course of the experiments, 2 recipients were sac-
rificed prematurely because of technical issues and were
excluded; no animals died after the procedure. We used 34 ani-
mals for this study.
OPERATIVE PROCEDURE
Donors
The donor animals were anaesthetized in a glass chamber by
inhaling 4% isoflurane. Thiopental (PentotalV
R
, Abbot AG, Baar,
Switzerland) at a dosage of 50 mg/kg body weight was adminis-
tered intraperitoneally. Heparin (LiqueminV
R
, Roche Pharma,
Rheinach, Switzerland) was administered by injection into the
penile vein (500 IU/kg body weight). A tracheostomy was per-
formed, and the animals were ventilated with a 14 GA catheter
(InsyteV
R
, Becton Dickinson, Sandy UT, USA) with fraction of
inspired oxygen = 1.0, a breathing frequency of 100 breaths/min
and a tidal volume of 8 ml/kg body weight by a rodent ventilator
(Model 683, Harvard Apparatus, South Natick, MA, USA). After
we cut the inferior vena cava and the left appendix of the heart,
we inserted a small silicon tube into the main pulmonary artery
(PA) via an incision in the right ventricle. Both lungs were flushed
with 20 ml of a low-potassium dextran solution (PerfadexV
R
,
Vitrolife Pharmaceutics, Uppsala, Sweden) at 20 cmH2O pressure.
The trachea was then tied with the lungs in the end respiratory
position. The heart–lung block was removed, and the left lung
was separated ex vivo. Small plastic cuffs were placed around the
PA and the left pulmonary vein (PV), the vessels were everted,
tied on the cuffs and fastened with 8-0 monofilament thread
(SurgiproV
R
, USSC, Norwalk, CT, USA). The grafts were stored in
low-potassium dextran solution.
Introduction of bone marrow-derived mesenchy-
mal stem cells in the graft
The hIL-10-BMSC (2 106 cells) in a volume of 250 ml was intro-
duced into the isolated graft, which was immediately stored at
10C until implantation in the recipient. The implantation pro-
cedure was usually performed within 2 h.
Recipients
The recipients were anaesthetized by breathing 4% isoflurane in
the glass chamber. Intubation was carried out using a 14-GA
catheter placed into the trachea. Anaesthesia was maintained
with 2.5% isoflurane. The recipient was ventilated with 1 cm
water positive end-expiratory pressure, a breathing frequency of
100 breaths/min and a tidal volume of 8 ml/kg body weight by a
rodent ventilator. A left thoracotomy was performed. The left
hilum was dissected, and microclips were placed on the left PA
and the left PV. The left main bronchus was ligated with 6-0
polyfilament thread (SofsilkV
R
, USSC, Norwalk, CT, USA) and cut.
An incision was made in both the PV and the PA. The vessels
were flushed with saline solution. The cuffs of the donor lung
were inserted into the recipients’ vessels, and 6-0 polyfilament
ligatures (Sofsilk) were placed around the cuffs and tied. The na-
tive PA and PV were cut-off beyond the anastomoses, and the
native lung was removed. A 9-0 monofilament running over-
and-over continuous suture (MonosofV
R
, Tyco Healthcare,
Wollerau Switzerland) was used for the bronchial anastomosis.
Ventilation was started. The microclips were removed to allow
retrograde and subsequently anterograde perfusion of the graft.
A small chest drain was inserted into the left pleural space; the
thoracotomy was closed with 3 layers of continuous sutures. The
chest drain was removed after spontaneous breathing was
restored; extubation followed.
Cyclosporin CsA (SandimmuneV
R
) (Novartis Pharma AG, Basel,
Switzerland) was diluted in castor oil in a ratio of 1:9 and injected
intraperitoneally every day. One ampoule of cyclosporine 50 mg
in 1 ml was added to 9 ml of castor oil to prepare 10 ml of the so-
lution. The volume of the daily administered cyclosporine solu-
tion depended on the body weight of the recipient.
ASSESSMENT
Graft function
Five days after the transplant, the recipient was preanaesthetized
in a glass chamber by inhaling 4% isoflurane and was given thio-
pental (50 mg/kg body weight) intraperitoneally. The animal was
ventilated via a tracheostomy with the Harvard Apparatus
Rodent Ventilator with fraction of inspired oxygen = 1.0, a fre-
quency of 100 breaths/min and a tidal volume of 8 ml/kg. A thor-
aco-laparotomy in the anterior midline was done. The right
hilum was dissected. Microvascular clips were placed on the right
main bronchus and the right PA to ventilate and perfuse only the
isolated left lung graft. Five minutes after the occlusion, 1 ml of
Figure 1: Flow cytometer analysis to determine the number of IL-10-trans-
fected BMSCs before administration in the animals. The histogram gives the
percentage of cells in relation to the largest fraction of living cells on the Y axis.
The X axis represents the intensity of the fluorescence. The red curve indicates
unstained cells (negative population), and the blue curve indicates the trans-
fected cells. Stem cells transfected with hIL-10 were gated based on the thresh-
old of the autofluorescence obtained from the non-transfected cells (red
graph). The transfected stem cells were then compared for the intensity of the
fluorescence, which is the measure of the transfection, indicated by the blue
line. The 2 blue curves are too close; the difference between them is less than
5%, which represents a small population of cells with slightly different transfec-
tion efficiency. IL-10: interleukin 10.
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blood was aspirated from the aortic arch to a syringe
(Radiometer Pico 50, Copenhagen, Denmark) for blood gas as-
sessment (Gastat-navi, Techno Medica Co. Ltd, Japan) using spe-
cial chips. We collected 1 ml of blood from the inferior vena cava
to measure the serum hIL-10 levels. Preocclusion blood was not
collected due to technical issues; it is not representative of the
graft function, and drawing blood twice from the same animal at
a short interval can be fatal. Subsequently, the inferior vena cava
and left appendix of the heart were incised, and a small silicon
tube was inserted into the main PA via an incision in the right
ventricle. The lungs were then flushed with 20 ml of a 0.9% saline
solution under pressure of 20 cmH2O. The heart–lung block was
explanted, and tissue samples were collected for histological ana-
lysis, wet-to-dry (W/D) ratio and protein extraction.
Histology
After explantation, the graft was isolated. The lung was cut into 3
pieces. The upper part was taken for histological analysis and
fixed in 4% paraformaldehyde. The middle section was frozen
for further analysis, and the lower portion was used to determine
the dry/wet ratio. After the graft was fixed in paraffin, sections
were cut and stained with haematoxylin and eosin. The histolo-
gical assessment was done by a trained lung pathologist in
blinded fashion according to the Working Formulation for
the Classification of Pulmonary Allograft Rejection of the
International Society for Heart and Lung Transplantation (ISHLT)
[1].
Enzyme-linked immunosorbent assay for human
interleukin 10 expression
Levels of hIL-10 circulating in the serum and in the lung graft were
measured using an hIL-10 immunoassay kit (R&D Systems,
Abingdon, UK) according to the manufacturer’s protocol. The anti-
body is specific, so no cross-reaction with rat IL-10 occurs. A total
of 1 ml of blood was drawn from the inferior vena cava on Day 5
at sacrifice, centrifuged and stored at -20C until we were ready
to make the measurements. The graft tissue was snap frozen, and
the total protein was extracted using the T-PERTM Tissue Protein
Extraction Reagent (Thermo Fisher Scientific, Waltham, MA, USA)
using 50 mg of tissue. The protein was extracted according to the
manufacturer’s protocol. After centrifugation, the sample was
stored at -20C until we were ready to make the measurements.
Wet-to-dry lung weight ratio
The lung W/D weight ratio was measured as an index of the ac-
cumulation of lung water in the graft. To measure the total
amount of lung water, the lung weight was measured immedi-
ately after its excision (wet weight). The lung tissue was then
dried in an oven at 60C for 48 h and reweighed as dry weight.
The W/D weight ratio was calculated by dividing the wet by the
dry weight.
Statistics
Analysis of variance was followed by a planned comparison with
the contrast vector. The level of rejection was graded using the
non-parametric Kruskal–Wallis analysis of variance and a post hoc
analysis with Dunnett’s test using the control group. A P-value
<0.05 was considered significant. All the analyses were performed
using GraphPad Prism 6 software (GraphPad Software, La Jolla,
CA, USA).
RESULTS
Rat bone marrow-derived mesenchymal stem cells
were successfully transfected and produced a sig-
nificant amount of human interleukin 10
Rat BMSCs were transfected by in vitro electroporation; 24 h
after the transfection, 17.1% of the cells were positive for hIL-10
(Fig. 1). The level of hIL-10 level found in the rBMSC 24 h after
transfection was 1184 ± 547.6 pg/ml.
High levels of human interleukin 10 were detected
in the sera and the grafts of the recipients after
pretreatment with human interleukin 10 bone
marrow-derived mesenchymal stem cells
Levels of hIL-10 were measured in the sera and the lung grafts of
the recipients in the treated group. Significantly higher levels of
hIL-10 were found in the sera and in the grafts (97.71 ± 13.57 pg/
ml and 76.86 ± 35.57 pg/ml, respectively) in Group C; no hIL-10
was noted in either control group (Groups A and B) at Day 5
using enzyme-linked immunosorbent assay.
Arterial blood gas levels indicated significantly
improved graft function after administration of
human interleukin 10 bone marrow-derived mes-
enchymal stem cells
Arterial partial pressure of oxygen levels in arterial blood meas-
ured 5 min after clamping the right hilum were significantly im-
proved in the hIL-10 BMSC group (Group C) (222.2 ±
40.38 mmHg) compared with those in the BMSC group (Group
B) (92.36 ± 20.92 mmHg) and in the CsA group (Group A)
(42.72 ± 18.00 mmHg) (Fig. 2A).
Graft oedema was lower in the recipients treated
with human interleukin 10 bone marrow-derived
mesenchymal stem cells
The W/D ratio in the grafts of the hIL-10 BMSC group was signifi-
cantly reduced in Group C (4.8 ± 1.19) compared with those in
Group A (CsA group) (9.36 ± 0.90). The ratio in the BMSC-only
group (Group B) was also reduced to 4.78 ± 0.62 with no signifi-
cant difference between the hIL-10 BMSC group (Group C) and
the BMSC-only group (Group B) (Fig. 2B).
The rejection score was significantly improved in
recipients treated with human interleukin 10 bone
marrow-derived mesenchymal stem cells
The histopathological assessment demonstrated improvement in
lung architecture in the hIL-10 BMSC group compared with the
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BMSC-only and CsA groups, as indicated by the rejection scores
of I–II A in the hIL-10 BMSC group (Group C) compared with II–
IIIA in the BMSC-only group (Group B) and III B in the CsA group
(Group A) (Table 1, Fig. 3).
DISCUSSION
This study demonstrates the beneficial effect of hIL-10 BMSC in
the graft of the recipients as a novel method to attenuate acute
graft rejection in a rat model of lung allotransplantation. This
method leads to better graft function, reduced graft oedema and
improved histological characteristics.
Immunomodulation to attain improved graft function and re-
duce acute rejection has been tried and tested in the past using
various methods. We also reported the use of gene therapy to
overexpress hIL-10 in the recipient to attenuate acute rejection
in a rat lung allotransplantation model [5]. IL-10 is a potent sup-
pressor of interferon c, tumour necrosis factor a, interleukin 1b
and interleukin 6 and facilitates the induction of tolerance after
allogenic transplantation [14]. It inhibits monocyte-/macro-
phage-dependent synthesis of cytokines by TH1 cells [15]. IL-10
also inhibits monocyte-/macrophage-dependent T-cell activa-
tion and antigen presentation as well as alloreactivity in vivo
[16]. Because it has these properties, IL-10 has been tested in
various transplantation models using different gene therapy
approaches [17, 18].
Despite recent advances, gene therapy is still not readily ac-
cepted in clinical applications. Therefore, novel techniques ap-
propriate for clinical translation need to be evaluated and
developed. In this study, our goal was to identify a potent partner
for IL-10 that could exert a synergetic, beneficial effect and at-
tenuate acute lung rejection by more effective anti-inflammatory
and immunosuppressive properties.
The immunomodulatory effect of mesenchymal stem cells was
initially reported to be the ability to suppress T-cell proliferation
[19]. It was further established that mesenchymal stem cells could
inhibit proliferation of B cells, natural killer cells and dendritic
cells. They also inhibit dendritic cells maturation, activation and
antigen presentation; cytokine secretion and cytotoxicity of T
and natural killer cells; and B-cell maturation and antibody secre-
tion [20, 21]. The use of stem cells as carriers for genes appears
promising [13, 22, 23]. In this study, we transfected BMSC with
interleukin-10 (hIL-10 BMSC) to evaluate its effect on acute lung
rejection in an allotransplant model. The synergetic effect of this
approach was evident in the improved lung function and histolo-
gical analysis.
However, a few in vivo studies using mesenchymal cells for
immunomodulation have reported controversial results [24–26].
Most of these studies were done using mice models in which the
cells were administered after transplantation. We administered
BMSC or hIL-10 BMSC prior to transplantation and achieved at-
tenuation of graft rejection using the hIL-10 BMSC in line with
the islet transplantation study in a rat model [27]. These results
indicate that hIL-10 BMSC exerts a protective effect. However,
we did not test BMSC or hIL-10 BMSC in our model after trans-
plantation to evaluate the effect post-transplant due to the pleo-
tropic nature of IL-10 [28]. Moreover, it has been shown in some
studies that BMSC collect at the site of injury [13]. Contrary to
these finding, we could not find BMSC or hIL-10 BMSC in the
lung graft (data not shown); however, we did find an increased
level of hIL-10 in the serum. We speculate that this increase is
due to the effect of the acute inflammatory process that leads to
cell death. However, this process needs further study using ad-
vance imaging systems. Finally, Kim et al. [27] reported the pro-
duction of IL-10 by the BMSC as an important immune
Figure 2: Function of the graft after 5 days, determined by measuring the arterial blood gas levels (A) and lung oedema, measured by determining the wet/dry ratio
(B) (n = 5 in each group). *P < 0.05; **P < 0.001. BMSC: bone marrow-derived mesenchymal stem cell; CsA: cyclosporine A; hIL-10: human interleukin 10.
Table 1: Histological grading using the classification system
of the International Society for Heart and Lung
Transplantation (ISHLT)
Vascular Airway
CsA A3 (A2–A4) B1 (B1–B0)
BMSC A1 (A1–A2) B0 (B1–B0) (1 B1)
hIL-10 BMSC A1 (A1–A0) B1 (B1–B0) (1 B1)
A: acute rejection; A0: no rejection; A1: minimal rejection; A2: mild rejec-
tion; A3: moderate rejection; A4: severe rejection; B: airway inflammation;
B0: no inflammation; B1: low-grade inflammation; B2: high-grade inflam-
mation; BMSC: bone marrow-derived mesenchymal stem cell; CsA:
cyclosporine A; hIL-10: human interleukin 10.
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modulator in their islet transplant study. We engineered the
BMSC to produce more IL-10, thereby enhancing the efficiency
of the BMSC and exerting a synergistic effect. We only tested
local delivery to the graft, because IL-10 acts as a proinflamma-
tory cytokine when it is overexpressed after the onset of an in-
flammatory process [29]. Multiple doses of BMSC alone after
transplantation could also be an interesting approach to further
enhance the beneficial effect; however, we did not test it.
Limitations
Although we have preliminary data suggesting that hIL10 BMSC
is a promising approach for treating acute graft rejection, we do
not yet have detailed mechanistic proof. Moreover, another limi-
tation is the short-term follow-up period. It would be interesting
to see the effect after a longer period. Also, our model does not
allow us to introduce more volume in the graft after implant-
ation; therefore, we were unable to test the effect of administer-
ing more BMSC after implantation. Although the current study
offers a good model, further preclinical study is required using a
larger animal model to prove the concept before clinical transla-
tion can occur.
CONCLUSION
In conclusion, hIL-10 BMSC is a promising immunomodulatory
agent for attenuating acute lung rejection. In addition, BMSCs
are easily isolated in culture and can be transfected in vitro using
non-viral vectors. Thus, modified BMSC therapy has the poten-
tial to reduce the severe toxicity of immunosuppressant drugs, to
suppress an immune rejection and to induce immune tolerance
following clinical transplantation. However, further investigations
are required to understand the detailed mechanisms. Moreover,
researchers have recently agreed to standardize the methods
used to characterize the immunomodulatory effect of mesen-
chymal cells for regulatory issue, thus facilitating advanced
clinical studies and their eventual acceptance for clinical applica-
tions [30].
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Supplementary material is available at EJCTS online.
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